Related Experiment Video
Updated: Apr 26, 2026
06:11
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.1K
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation
David L Masica1, Shuli Li, Christopher Douville
1Department of Biomedical Engineering, Institute for Computational Medicine, The Johns Hopkins University, Baltimore, MD, USA, david.masica@gmail.com.
Human Genetics
|August 11, 2014
Summary
Predicting head and neck cancer survival from TP53 mutations is crucial. The Poeta rules, with or without splice-site considerations, showed the best, though limited, prognostic ability for progression-free survival.
Area of Science:
- Oncology
- Genetics
- Bioinformatics
Background:
- TP53 mutations are common in head and neck squamous cell carcinomas (HNSCCs) and can impact patient prognosis.
- Predictive frameworks for TP53 mutations are needed to guide clinical decisions.
- The clinical utility of various bioinformatics and functional prediction methods remains unclear.
Purpose of the Study:
- To evaluate the prognostic performance of 15 different methods in predicting HNSCC patient survival based on TP53 mutations.
- To identify methods that can accurately categorize TP53 mutations as "disruptive" or "non-disruptive" for survival prediction.
Main Methods:
- Utilized TP53 mutation and clinical data from 420 HNSCC patients (224 with TP53 mutations) from the ECOG E4393 trial.
- Assessed 15 prediction methods including computational tools (SIFT, PolyPhen-2, Align-GVGD), in-house algorithms (POSE, VEST), Poeta rules (with/without splice-site considerations), mutation location, and a functional yeast assay.
- Compared overall survival (OS) and progression-free survival (PFS) between "disruptive" and "non-disruptive" mutation groups for each method.
Main Results:
- The Poeta rules, particularly with splice-site modification, demonstrated superior performance compared to other methods.
- Both Poeta rule variations identified "disruptive" TP53 mutations as significantly associated with worse PFS (P=0.011 and P=0.027, respectively).
- Prognostic performance for OS was marginally significant (Poeta rules + splice rules, P=0.089; Poeta rules, P=0.053), and overall prognostic performance across methods was generally low.
Conclusions:
- The Poeta et al. rules, especially when accounting for splice-site mutations, offer the most promising approach for predicting survival outcomes in TP53-mutated HNSCC.
- Current methods show limited prognostic value, highlighting the need for further development and validation.
- Accurate prediction of functional and clinical significance of TP53 mutations is essential for improving HNSCC patient management.
